Introduction {#s1}
============

Alzheimer's disease (AD) constitutes the most prominent cause of late-life dementia, affecting over 50 million individuals. Additionally, AD represents one of the leading causes of death worldwide ([@B1]). Although considerable progress has been made in neuroscience, there are currently no available drug treatments curing the disease, thus highlighting that it is accompanied by significant social and economic burden ([@B3]; [@B2]). The majority of AD clinical cases develop symptoms beyond the age of 65 and are collectively referred to as sporadic AD (SAD). Familial AD (FAD) incidents, which pertain only to 2--5% of AD cases, develop early-onset symptoms and have been linked to mutations in genes such as *APP, PSEN1,* and *PSEN2* ([@B4]).

AD is caused by neuronal deposition and subsequent toxicity of amyloid-beta (Aβ)- and tau hyperphosphorylation-derived neurofibrillary tangles (NFTs) ([@B6]; [@B5]; [@B7]). In the AD brain, Aβ plaques are formed by aggregation of monomeric Aβ peptides into toxic Aβ oligomers, which subsequently generate the insoluble fibrils. Aβ plaque formation has been shown to trigger inflammatory responses and Reactive Oxygen Species (ROS) production, resulting in neuronal death ([@B9]; [@B8]; [@B7]). Additionally, toxic Aβ species may trigger caspase-associated apoptosis, following their transfer into neuronal cells ([@B9]; [@B8]; [@B7]). In healthy individuals, β- and γ-secretases proteolyze the amyloid precursor protein (APP) to soluble and non-toxic Aβ monomers, whereas in AD patients, Aβ plaques are formed due to increased production or insufficient removal of Aβ peptides ([@B10]). Moreover, extracellular matrix (ECM) components such as heparin sulfate proteoglycans (HSPG) have been shown to foster amyloid plaque formation ([@B11]). Aβ peptide accumulation may synergize with tau-related NFT formation to contribute to AD manifestation, as indicated by a number of studies ([@B12]).

Several limitations accompany the implementation of transgenic mice in elucidating the molecular mechanisms underlying AD pathophysiology, such as the inability to capture tau pathology and the development of AD features early in life ([@B13]; [@B15]; [@B16]; [@B14]). Additionally, monolayer neuronal cultures from AD patients lack plaques and tangles and express toxic proteins, which also limit their potential use as model systems ([@B2]). Thus, novel systems are required to model AD development and serve as platforms for the discovery of effective AD treatments. In this literature review, we aim to provide an overview of recent advances regarding the development of brain organoids as a humanized model system against AD.

iPSCs in AD Modeling {#s1_1}
--------------------

The establishment and optimization of protocols allowing the reprogramming of human somatic cells into induced pluripotent stem cells (iPSC) opened new avenues in disease modeling ([@B17]). Human pluripotent stem cells (hPSC) include blastocyst-derived human embryonic stem cells (ESC) and hiPSCs reprogrammed from somatic cells. HPSCs display unlimited self-renewal and can differentiate toward mesoderm, endoderm, or ectoderm ([@B18]). Three methods have been so far established to capture the AD phenotype using hPSCs. The first method pertains to chemical induction with Aβ42 oligomers or Aβ42 inducers, such as aftin5. In this method, neural cells derived from AD-free hPSCs are induced to develop AD phenotypes ([@B20]; [@B19]). Although certain pathophysiological features of the disease such as neuronal cytotoxicity can be displayed by implementing this method, induced neuronal cells usually lack other features such as extracellular Aβ plaque formation. The second method is based on the generation of iPSCs from somatic cells carrying known AD mutations and subsequent differentiation of those iPSCs into various types of neuronal cells. iPSCs deriving from FAD patients usually carry *PS1, PS2, or APP* genomic mutations, whereas those deriving from SAD patients carry *APOE4* mutations ([@B21]). In the third method, lentiviral transduction or CRISPR-Cas9-mediated genomic editing are implemented in order to induce overexpression or expression of mutant APP, PS1, PS2, and APOE4 proteins in healthy hPSCs ([@B23]; [@B22]). Additionally, by utilizing human ESC-derived neurons ectopically expressing APOE2/E3/E4, it was shown that all APOE isoforms could induce Aβ and APP production, albeit to a different extent, with APOE4 being the most potent isoform ([@B22]). The majority of hPSC-based AD models implemented either two-dimensional (2D) or embryoid body (EB) differentiation methodologies to produce different types of neurons, including forebrain, cortical glutamatergic, GABAergic, and cholinergic neurons ([@B24]; [@B25]).

2D cell culture models of FAD and SAD based on patient-derived iPSCs have been shown to resemble some features of AD pathophysiology, such as intracellular accumulation of soluble Aβ species, aggregation of insoluble Aβ species, and tau hyperphosphorylation ([@B27]; [@B26]). Moreover, iPSC-derived neurons from FAD patients can successfully capture important features of AD pathogenesis at early stages ([@B28]). However, while iPSC- or ESC-derived neurons cultured in monolayer have yielded important findings, they fail to present various morphological and functional properties of the human brain, which poses limitations in their use as model systems for neurodegenerative diseases. Neuronal maturation and development of synapse connections are governed by cell-cell and ligand-receptor signaling, which are not sufficiently established when neurons are cultured in monolayer ([@B2]). Monolayer cultures do not offer accurate representations of the number, functional interactions, and regulatory functions typically observed in oligodendrocytes, astrocytes, and microglia in the human brain. Additionally, it is difficult to faithfully mimic neuronal maturation in monolayer cultures, as the *in vivo* process takes place on much longer timescales than monolayer cultures can be maintained ([@B29]; [@B30]). In the case of AD, in particular, 2D cultures fail to display aggregation of extracellular β-amyloids, as only low Aβ species levels are produced even in the presence of the most prominent FAD genetic mutations. Moreover, the absence of interstitial compartment is believed to inhibit extracellular β-amyloid aggregation in 2D cultures ([@B31]).

Modeling AD With hPSC-Derived Organoids {#s1_2}
---------------------------------------

The limitations of monolayer cultures triggered the development of additional *in vitro* model systems capable of resembling human brain architecture and function more accurately than before ([@B33]; [@B32]). The improvement of protocols for *in vitro* iPSC differentiation led to the establishment of "organoids", which are three-dimensional (3D) self-organized structures displaying morphological and functional similarities with complex organs, such as the brain. Brain organoid formation relies on the self-organization ability of hiPSCs, which may be facilitated by additional exogenous components, for example matrigel ([@B34]; [@B35]). Brain organoids develop to display organized structures, resembling distinct regions of the brain, thus maintaining hallmarks of key developmental processes involved in brain formation ([@B36]). Over the past few years, various attempts have been made to model specific brain substructures with the use of organoids. In this context, forebrain, midbrain, hippocampus, and retinal organoids have been developed from hiPSCs ([@B37]). A major point of discussion regarding the optimization of organoid formation protocols is whether cell fate induction should be facilitated through the addition of exogenous morphogens and signaling molecules or not facilitated at all. Several protocols favor spontaneous neural induction by avoiding supplementation of organoid media with exogenous factors, thereby resulting in the acquisition of heterogeneous cell populations, corresponding to various brain regions ([@B36]; [@B38]; [@B39]). Undirected organoids, often grown in ECM, stochastically give rise to cells corresponding to multiple brain sections ranging from the retina to hindbrain ([**Figure 1A**](#f1){ref-type="fig"}) ([@B36]). One major limitation of spontaneous neural induction is that a proportion of cells are randomly differentiated into non-ectodermal cell types ([@B38]; [@B39]). Hence, most current efforts are based on protocols optimizing the application of extrinsic cues to induce neuronal differentiation.

![Organoid formation technologies from human pluripotent stem cells (hPSCs) and primary tissue. **(A)** Guided brain organoids generated from hPSCs through embryoid body (EB) formation. The process requires extrinsic factors, such as extracellular matrix (ECM) and exogenous differentiation signals. The presence of different cell types in the organoids is indicated by different colors (blue, red and green) **(B)** Unguided brain organoids generated from hPSCs upon stem cell self-organization and self-assembly, in the absence of extrinsic factors. With this method, non-ectodermal cell types may be incorporated in brain organoids (yellow color) **(C)** Primary tissue-derived organoids are generated by human epithelial tissue of any age. Described protocols include tissue digestion and subsequent use of defined cell culture media supplemented with tissue-specific growth factors. Organoids are embedded in ECM.](fphar-11-00396-g001){#f1}

In guided brain formation, defined combinations of exogenously applied factors direct the *in vitro* specification of stem cell aggregates into organoids ([**Figure 1B**](#f1){ref-type="fig"}) ([@B41]; [@B40]; [@B42]; [@B2]). Guided methodologies for brain organoid generation were first described by the Sasai group, which conceived and optimized targeted 3D differentiation protocols based on culturing EB aggregates in serum-free conditions ([@B44]; [@B43]; [@B32]; [@B45]). Directed organoid cultures have the advantage of containing different cell lineages at relatively stable proportions, thereby limiting potential variations across different batches and cell lines ([@B46]). Organoids mature over a period of many months ([@B46]), achieving a diameter of several millimeters, and contain heterogeneous cell types including neuronal subtypes, outer radial glia cells, astrocytes, and oligodendrocytes ([@B38]; [@B42]; [@B47]; [@B39]; [@B46]; [@B2]).

In order to model inter-regional interactions pertaining to brain physiology, several groups have attempted to differentiate hPSCs toward distinct brain region-specific organoids before fusing them together to allow the formation of "assembloids" integrating multiple region identities ([@B48]; [@B47]; [@B49]). Along those lines, assembloids have formed *via* fusion of dorsal and ventral forebrain organoids ([@B47]). In those structures, intraneurons originating from the ventral region translocate to the dorsal region, thus resembling the *in vivo* situation.

Brain organoids generated from hPSCs have been recently implemented to model various neurological disorders such as autism ([@B40]; [@B47]), microcephaly ([@B17]), Parkinson's disease ([@B50]), and Zika virus infections ([@B42]). The first successful attempt in using organoids to model AD was based on human neuronal progenitor cells genetically manipulated to overexpress mutant PS1 and APP ([@B31]). This methodology allowed the simultaneous presence of β-amyloid- and tau-related features in a single 3D model system. Those 3D structures carrying FAD mutations displayed increased detergent-resistant accumulations of phosphorylated tau, together with filamentous tau.

A sophisticated model of AD cerebral organoids was recently generated from FAD patient- or Down patient-derived iPSCs ([@B51]). In this model, brain organoids displayed progressive accumulation of amyloidogenic Aβ peptides, accompanied by the development of structures strongly resembling amyloid plaques and NFTs. These phenotypes were absent in cerebral organoids derived from "control" templates such as healthy hiPSC, mouse ESCs, or mouse iPSCs ([@B51]).

Recently a new 3D human tri-culture model including neurons, astrocytes, and microglia was developed to model AD with the use of microfluidics ([@B52]). The model displayed critical features of AD pathology, such as β-amyloid aggregation, tau hyperphosphorylation, neuroinflammatory activity, microglial recruitment, axonal cleavage resulting from neurotoxic activities, and release of NO with deleterious effects on AD neurons and astrocytes ([@B52]).

Use of hPSC-Derived Organoids as a Treatment Platform for AD {#s1_3}
------------------------------------------------------------

Two studies have implemented AD brain organoids in order to assess the effect of pharmacological agents on various disease features. Both studies used primarily modulators of β- or γ-secretase and were able to observe reductions in Aβ peptide levels, as well as alterations in tau pathology, in line with previous reports involving iPSCs. Choi et al. (2014) developed 3D-differentiated neuronal cells carrying FAD mutations, and importantly, demonstrated that perturbation of β-amyloid generation with β- or γ-secretase inhibitors attenuated both β-amyloid and tau-related pathology, indicating that tau-dependent phenotypes may be driven by excessive accumulation of Aβ species as a result of FAD mutations ([@B31]). Additionally, the use of glycogen synthase kinase 3 (GSK3) was found to regulate β-amyloid-mediated tau phosphorylation in that system. Thus, that study constituted the first attempt to show that stem cell-derived 3D *in vitro* systems can potentially serve as drug treatment platforms against AD ([@B31]).

In a more recent study by Raja et al. (2016), hPSC-derived organoids from FAD patients again exhibited AD-like pathophysiological features, including amyloid aggregation, tau hyperphosphorylation, and endosome abnormalities, in an age-dependent fashion ([@B53]). The authors showed that the 3D system they developed could be easily subjected to experimental manipulation and serve as a potential drug treatment platform. The authors found that treatment of FAD patient-derived organoids with γ-secretase inhibitor compound E or BACE-1 β-secretase inhibitor (β-secretase inhibitor IV) partially reversed both amyloid and tau pathology. Additionally, in contrast to published data not supporting a pivotal role of amyloids in AD manifestation ([@B55]; [@B54]), the authors showed that inhibition of Aβ species limited tau hyperphosphorylation only after Aβ reduction was observed, suggesting that Aβ accumulation-driven phenotypes in AD may emerge prior to tauopathy ([@B53]).

Limitations of hPSC-Derived Organoids in Modeling AD {#s1_4}
----------------------------------------------------

HPSC-derived brain organoids display most of the advantages of 2D cultures, while offering the ability to model complex cell-cell interactions, as they usually contain more than one cell population. Because of their advantages, hPSC-derived brain organoids have been utilized to model AD and examine the impact of pharmacological factors on disease progression, however, serious technical hurdles are still required to be resolved. Additionally, the organoid generation technology applied so far to model neurodegenerative diseases, including AD, needs to be reviewed and updated.

One critical limitation to modeling AD with the use of hPSC-derived organoids relates to aging. Aging constitutes the main risk factor to develop AD, especially in the case of SAD, and the process of aging is accompanied by numerous genetic alterations resulting in changes in the overall cellular transcriptional profile ([@B56]; [@B14]). However, iPSC-derived neural cells display a transcriptional profile similar to prenatal brain ([@B38]; [@B14]), thereby making it challenging to recapitulate aging-related phenotypes.

Another important limitation is the lack of complete vascularization. Vascularization is critical to mimic the *in vivo* situation in the brain, as maturation of neuronal cells cannot be accomplished without sufficient oxygen and nutrient supply. Insufficient neuronal cell maturation results in perturbed synapse formation, whereas lack of vascularization overall limits organoid culturing periods ([@B36]; [@B37]). Lack of vascularization additionally prevents modeling important aspects of brain physiology, such as the blood brain barrier ([@B57]). Along these lines, cerebral organoids produced from AD- or Down patient-derived iPSCs structurally resemble the human cortex, however they contain only neurons and glial cells, lacking oligodendrocytes. Additionally, those organoids fail to establish active synapses ([@B51]). To overcome vascularization-related hurdles, heterotypic cultures combining mouse brain cells or brain progenitors with endothelial and mesenchymal stem cells have been recently used to generate 3D organ buds ([@B58]), however, the functionality of that system has yet to be addressed in mice and humans. Additionally, it has been shown that although brain organoids are able to incorporate exogenous endothelial cells, the resulting endothelial network may not be functional ([@B35]).

HPSC-derived organoid models are so far challenged by low reproducibility and homogeneity. Organoid differentiation protocols relying on hPSC self-organization, in particular, lead to variable outcomes. Brain organoids differ from each other in size and structure, which are limiting factors in accurately modeling diseases such as AD. The small size, in particular, of hPSC-derived organoids comprises an important limitation in modeling human brain development, especially at later stages ([@B59]). Microfluidics, spinning bioreactors and orbital shakers combining new biomaterials and culture methodologies, have been proposed as new avenues to control neural patterning more accurately and improve oxygen and nutrient supply to the organoid interior ([@B60]; [@B42]; [@B61]; [@B7]).

Improvements in culturing conditions and the use of novel biomaterials might also help rectify another important limitation encountered in hPSC-derived organoid cultures, which is insufficient immune cell representation. Several brain organoid systems developed so far are characterized by the presence of astrocytes, but no microglial cells ([@B62]). The absence of microglial cells could be also attributed to their distinct embryonic origin, as they derive from yolk sac erythromyeloid precursors ([@B63]; [@B64]).

HPSC-derived organoids predominantly rely on the process of somatic cell reprogramming, which has been extensively linked to increased risk of genomic instability, as iPSCs may often carry mutations related to known tumorigenic loci ([@B67]; [@B65]; [@B66]). This implication poses serious limitations to the use of hPSC-derived organoids in modeling human disease. Additionally, genomic analyses of early passage iPSCs have indicated that they might retain "epigenetic memory" related to their previous fate, by displaying DNA methylation patterns encountered in somatic cells, at regions proximal to CpG islands. Consequently, this leads to variations in gene expression which might affect hPSC usage as organoid generation templates ([@B69]; [@B70]; [@B71]; [@B68]; [@B72]).

Another limitation related to hPSC-derived organoids is that most hPSC cultures are feeder cell-dependent, adding to the complexity of the culturing protocols and increasing the risk of underlying cell culture infections. A shift to feeder-free culturing conditions could increase reproducibility across cell lines and laboratories ([@B61]; [@B73]). Due to the above limitations, hPSC-derived organoid cultures need to be constantly compared to independent batches of multiple hPSC lines and adequately assessed for their capacity to produce consistent results, before being put forward as powerful disease model systems.

Future Perspectives of the Organoid Technology {#s1_5}
----------------------------------------------

Since 2009, a 3D *in vitro* culture system for several organs, such as small intestine, colon, stomach, prostate, liver, pancreas, breast, lung, and skin has been established ([@B79]; [@B74]; [@B78]; [@B77]; [@B75]; [@B76]; [@B80]; [@B82]; [@B81]), based on stimulating the self-renewal capacity of the underlying stem cell populations. Culturing of the above tissues in defined conditioned media results in the formation of 3D mini-tissues, also called organoids. Those primary tissue-derived organoids can be established from mouse and human tissue of any age, they do not require additional cell types to stimulate growth, are genetically stable and can retain the *in vivo* organization and development of the tissue they derive from. More importantly, they do not depend on iPSC technology and their long-term culture has been optimized through various protocols depending on the tissue ([**Figure 1C**](#f1){ref-type="fig"}) ([@B83]).

Patient-derived organoids offer a unique model system, as it resembles the *in vivo* situation more closely than any other cell culture so far. All attempts, however, to generate organoids immediately derived from primary material have been focused on epithelial tissue. Given that the study of neurodegenerative disorders requires the establishment and maintenance of non-epithelial cell cultures, one of the most important future challenges is to adapt the current patient-derived organoid technology to model diseases encountered in non-epithelial tissues. Taking into account the numerous advantages of patient-derived organoids, the field is soon expected to expand this cutting edge technology to encompass non-epithelial tissue. In doing so, the biggest challenge would be to define the optimal media composition supporting the *in vitro* generation and maintenance of patient-derived brain organoids. The next step following the establishment of hPSC-free brain organoids would be to implement means of genetic manipulation and drug delivery, allowing for personalized treatment approaches. Along those lines, and considering the advantages of patient-derived brain organoids with regards to functionality and biosafety, the potential of utilizing the system in regenerative medicine would be greater than any other system so far.

Discussion {#s2}
==========

Several attempts have been made to model and pharmacologically target neurodegenerative diseases, such as AD, with the use of brain organoids. So far, brain organoid generation attempts have been mostly focused on somatic cell reprogramming, a process in which patient-derived somatic cells are induced to become hPSCs ([@B2]). HPSCs can be subsequently differentiated into monolayer neuronal cultures or brain organoids, which are 3D neural cell aggregates resembling various brain regions. In the case of AD, there have been several attempts to generate brain organoids using the hPSC technology ([@B53]; [@B19]; [@B14]; [@B84]) and a lot of progress has been made both in modeling the disease and assessing the effectiveness of drugs like γ-secretase inhibitors to reverse AD-related phenotypes. With regards to their differentiation pattern, unguided brain organoids have shown suitability in modeling cell-lineage diversity in whole brain development, whereas directed brain organoids may be fused to form assembloids in order to capture and study processes linked to specific brain regions, including the hippocampal loss in AD ([@B48]; [@B47]; [@B49]).

HPSC-derived organoids are accompanied by a series of limitations, such as lack of or limited integration of important cell types (e.g. microglial cells and oligodendrocytes), lack of distinct cortical neuronal layer formation, no evidence of gyrification, nor complex neuronal circuitry ([@B14]; [@B84]). Additionally, the iPSC technology itself poses limitations with regards to safety, genomic stability, and reproducibility.

Current organoid models are majorly derived from the epithelium of various organs. Established protocols for generating primary tissue-derived organoids could overcome the aging-related issues of hPSC-derived organoids, as primary tissue-derived organoids can be established from mammalian tissue of any age. Additionally, primary tissue-derived organoids are based on more stringent differentiation protocols, in contrast to protocols relying on hPSC self-organization. It has been widely reported that stochasticity in the hPSC differentiation process culminates in unpredictable outcomes in brain organoid cultures, adding to reproducibility issues. The challenge of adapting epithelial organoid generation protocols to meet the requirements of non-epithelial tissue culture still remains.
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